Pharma BD Deal Intelligence
J&J paid $14.6B for Intra-Cellular Therapies to acquire Caplyta (lumateperone) for schizophrenia and bipolar depression. The deal doubled down on J&J's neuroscience franchise alongside Spravato, betting that CNS remains an underserved mega-market despite decades of pharma retreat.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J to buy psychiatric drug developer Intra-Cellular Therapies for $14.6 billion, adding schizophrenia drug CAPLYTA at a 39% premium on the companys closing…
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers' reentry into neuroscience…
J&J Q1 2026 results (released 2026-04-14): Caplyta (lumateperone) reported worldwide net sales of $270M for the quarter, all U.S. CAPLYTA continued to build…
Source summaries from our enrichment pipeline; follow links for originals.
All 18 sources with sentiment breakdown →
J&J acquired Intra-Cellular Therapies for $14.6B for neurological drugs.
21M US cases/yr · $18.5B US atypical antipsychotic + adjunct MDD market (2024) · 5000 Leerink peak Caplyta sales estimate (USD MM)
Schizophrenia is a chronic, severe mental disorder characterized by hallucinations, delusions, disorganized thinking, and cognitive impairment. Per NIMH epidemiologic data, the 12-month prevalence of schizophrenia and related psychotic disorders is approximately 0.25-0.64% of US adults, translating to roughly 2.4 million affected individuals. Onset typically occurs in late adolescence to early adulthood. Bipolar disorder is a mood disorder marked by alternating manic and depressive episodes; NIMH estimates 12-month prevalence at 2.8% of US adults (~7 million), with bipolar I and II depression representing the most treatment-refractory phases. Major depressive disorder (MDD) affects approximately 8.3% of US adults annually (21 million), with an estimated 30-40% failing to achieve remission on first-line antidepressants and requiring adjunctive therapy. The three indications share significant comorbidity — up to 50% of schizophrenia patients experience depressive symptoms. First-line antipsychotic therapies (atypicals such as olanzapine, quetiapine, aripiprazole) carry substantial metabolic burden including weight gain, dyslipidemia, and hyperglycemia, creating unmet need for agents with improved tolerability. Lumateperone (Caplyta) addresses this gap via a distinct serotonin-dopamine-glutamate modulator mechanism with placebo-like metabolic and sexual side-effect profiles, enabling broader and longer-duration use.
The adjunctive MDD and atypical antipsychotic segment is defined by metabolic-safety differentiation. Serotonin-dopamine-glutamate modulators: Caplyta (lumateperone, Intra-Cellular / now J&J) now approved for schizophrenia, bipolar depression, and adjunctive MDD (Nov 2025), with placebo-like metabolic signal. Atypical dopamine partial agonists: Rexulti (brexpiprazole, Otsuka/Lundbeck) — established adjunctive MDD, metabolic burden; Abilify (aripiprazole, Otsuka/BMS) — generic, first-line adjunct. Full dopamine D2 antagonists: Vraylar (cariprazine, AbbVie/Gedeon Richter) — bipolar depression and adjunctive MDD competitor. Muscarinic agonists (emerging class): Cobenfy (xanomeline-trospium, BMS, approved Sep 2024) — first non-D2 schizophrenia approval in 70 years, under evaluation for adjunct MDD. NMDA-targeted: Auvelity (dextromethorphan-bupropion, Axsome) — rapid-onset MDD. Caplyta's positioning leans on tolerability and breadth across three CNS indications; principal threats come from Cobenfy (novel muscarinic mechanism) and generic atypicals post-LOE.
7M US cases/yr · $5.0B US Bipolar Rx Market
Bipolar depression represents the depressive episodes in bipolar I and II disorder, affecting approximately 7 million US adults. Depressive episodes are more frequent and disabling than manic episodes, yet treatment options have historically been limited.
CAPLYTA is the first oral antipsychotic approved as both monotherapy and adjunctive therapy for bipolar depression across both bipolar I and II, a significant differentiator versus Latuda (generic) and Vraylar.
3.5M US cases/yr · $12.0B US Antipsychotics Market
Schizophrenia is a chronic, severe mental disorder affecting how a person thinks, feels, and behaves. Characterized by hallucinations, delusions, and cognitive impairment, it is treated primarily with antipsychotic medications but significant unmet need remains for agents with better tolerability profiles.
Market dominated by generic atypical antipsychotics (olanzapine, risperidone, quetiapine). CAPLYTA differentiated by favorable metabolic and movement disorder profile. Key competitors include Cobenfy (KarXT, BMS) and long-acting injectables.
J&J announces acquisition at JP Morgan Healthcare Conference, targeting Caplyta franchise.
J&J acquires Intra-Cellular at $132/share (39% premium) to solidify neuroscience leadership with Caplyta.
Pipeline asset ITI-1284 progresses in Phase 2 for GAD and Alzheimer psychosis. Part of Johnson & Johnson's $14.6B deal to acquire Intra-Cellular Therapies.
J&J revises 2025 EPS dilution from -$0.30-0.35 to -$0.25, improving to -$0.21 in 2026.
FDA approves Caplyta as adjunctive therapy for major depressive disorder, first approval under J&J.
MDD approval expands Caplyta TAM significantly. Dilution better than projected. Pipeline advancing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Intra-Cellular Therapies (this deal) | 2025 | $14.6B | 76 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2025 deals · Johnson & Johnson deals · Neurology deals